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Background. Morbidity and mortality remain high among hospitalized patients infected with human immuno-
deﬁciency virus (HIV) in sub-Saharan Africa despite widespread availability of antiretroviral therapy. Severe anemia
is likely one important driver, and some evidence suggests that blood transfusions may accelerate HIV progression
and paradoxically increase short-term mortality. We investigated the relationship between anemia, blood transfu-
sions, and mortality in a South African district hospital.
Methods. Unselected consecutive HIV-infected adults requiring acute medical admission to a Cape Town town-
ship district hospital were recruited. Admission hemoglobin concentrations were used to classify anemia severity
according to World Health Organization/AIDS Clinical Trials Group criteria. Vital status was determined at 90
days, and Cox regression analyses were used to determine independent predictors of mortality.
Results. Of 585 HIV-infected patients enrolled, 578 (98.8%) were included in the analysis. Anemia was detected in
84.8% of patients and was severe (hemoglobin, 6.5–7.9 g/dL) or life-threatening (hemoglobin, <6.5 g/dL) in 17.3% and
13.3%, respectively. Within 90 days of the date of admission, 13.5% (n = 78) patients received at least 1 blood transfusion
with red cell concentrate and 77 (13.3%) patients died. In univariable analysis, baseline hemoglobin and receipt of blood
transfusion were associated with increased mortality risk. However, in multivariable analysis, neither hemoglobin nor
receipt of a blood transfusion were independently associated with greater mortality risk. Acquired immune deﬁciency
syndrome-deﬁning illnesses other than tuberculosis and impaired renal function independently predicted mortality.
Conclusions. Newly admitted HIV-infected adults had a high prevalence of severe or life-threatening anemia and
blood transfusions were frequently required. However, after adjustment for confounders, blood transfusions did not con-
fer an increased mortality risk.
Keywords. Africa; AIDS; anemia; blood transfusion; HIV; hospitalized; mortality.
Despite the unprecedented scale-up of antiretroviral
therapy (ART) in sub-Saharan Africa over the last dec-
ade, morbidity and mortality among hospitalized inpa-
tient persons infected with human immunodeﬁciency
virus (HIV) remain very high [1, 2]. Anemia is the
most common hematological complication of HIV dis-
ease, it is highly prevalent among persons living with
HIV/acquired immune deﬁciency syndrome (AIDS)
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in sub-Saharan Africa [3–6], and it may be an important driver
of morbidity and mortality among inpatients infected with HIV.
HIV-related anemia is associated with fatigue, decreased quality
of life [7], and a greatly increased mortality risk [8–11]. Al-
though the South African HIV Clinician’s Society has published
recommendations on the management of anemia and blood
transfusions among patients infected with HIV, there are no
normative international guidelines for the management of
HIV-related anemia in sub-Saharan Africa or other resource-
limited settings [12].
ART is associated with substantial hemoglobin recovery, re-
sulting in resolution of anemia in a majority of HIV-infected
African patients without additional speciﬁc hematological in-
terventions [3, 5, 6, 13, 14]. ART is thus the key therapeutic
intervention for HIV-related chronic anemia, but weeks
or months may be required for adequate hemoglobin recovery
to occur with ART. However, patients may also present acutely
to healthcare settings with severe or life-threatening anemia, re-
quiring immediate correction. This may include administration
of blood transfusions when considered clinically appropriate.
Although it may be expected that HIV-infected hospitalized
patients in sub-Saharan Africa have high transfusion require-
ments, few data have been published data on this topic [15–
17]. In addition, some evidence suggests that blood transfusions
are associated with modest increases in plasma HIV-1 RNA lev-
els and increased mortality risk [11, 18–20]. This has led some
clinicians to conclude that transfusions should be used sparing-
ly among patients infected with HIV [12]. The limited evidence
to date to support such caution is derived exclusively from
North America, and thus this issue has not yet been investigated
in sub-Saharan Africa, where the prevalence of HIV-related
anemia remains high. Therefore, we sought to determine
whether blood transfusions were independently associated
with an increased mortality risk among HIV-infected adults re-
quiring acute medical admission to a district-level hospital in
Cape Town, South Africa.
METHODS
GF Jooste Hospital served as the public sector adult referral hos-
pital for a community of approximately 1.3 million people at the
time of the study. Patients seen at public sector primary care, HIV,
or tuberculosis (TB) clinics or by private general practitioners
could be referred to the hospital. Those ill enough to require ad-
mission were admitted to the medical ward. The local antenatal
HIV seroprevalence is approximately 35%, and the large burden
of TB is well described [21, 22]. The Research Ethics Committees
of the University of Cape Town and the London School of Hy-
giene & Tropical Medicine approved this study, and all patients
provided written informed consent before participation.
This study was nested within a prospective cohort study in
which the parent study sought to evaluate new approaches to
the rapid diagnosis of HIV-associated TB [23]. HIV-infected
persons ≥18 years of age requiring acute admission to a medical
ward were eligible for inclusion. Patients were prospectively re-
cruited 4 days per week from June 2012 to October 2013. Any
patient with an unknown or previously negative test was offered
HIV testing. A positive HIV serostatus was conﬁrmed in paral-
lel by 2 rapid assays.
Procedures
Upon enrollment, demographic and clinical details were re-
corded for all patients. Patients were systematically investigated
for TB by obtaining a combination of respiratory and non-
respiratory clinical specimens as previously described [23].
A venous blood sample was collected for the measurement of
C-reactive protein (CRP) and HIV viral load in keeping with
the protocol of the parent study. Hemoglobin concentrations
were measured using the ADVIA 2120 hematology analyzer
(Siemens Healthcare Diagnostics, Erlangen, Germany).
Patient Outcomes and Use of Blood Products
Mortality and loss to follow-up (LTFU) within 90 days after
study entry was determined using patient case notes and the
medical ward register in addition to 6 regional and national
electronic health record databases [24]. All data sources were
cross-referenced for consistency, and any discrepancies in pa-
tient outcomes were resolved.
The decision to administer a blood transfusion was made
by the clinical team responsible for the patient, and there
was no hospital guideline deﬁning a recommended hemoglo-
bin “threshold” level for blood transfusion. Electronic records
from the local Red Cross Hospital blood bank were searched
to identify patients receiving a blood transfusion with red
blood cell concentrate (RCC) between 6 months before
study enrollment to 6 months after study enrollment (12-
month interval). However, because transfusions adminis-
tered between 7 days prior to and 90 days after the study
admission date were most likely to be associated with mortal-
ity, only blood transfusion data from this time interval was
utilized. Costs associated with blood products and transfu-
sion services were also extracted from billing invoices from
the Western Province blood transfusion service. Costs were
estimated “top-down” and included fees associated with
blood products, screening and testing, service fees, and asso-
ciated value-added tax; fees associated with clinician services
and medical supplies necessary for transfusions were not
included.
Data Analysis and Deﬁnitions
Analyses were restricted to data from patients with hemoglobin
levels available from the time of hospital admission. Admission
hemoglobin levels as well as full blood counts, blood chemistry
(including creatinine), and the results of all mycobacterial and
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other microbiological investigations were extracted from the
National Health Laboratory Service computerized data system.
Anemia severity was classiﬁed into mutually exclusive groups
using admission hemoglobin levels according to a combination
of World Health Organization [25] and AIDS Clinical Trials
Group (ACTG) [26] criteria. These are as follows: no anemia
(≥13.0 g/dL for men, ≥12.0 g/dL for females), mild anemia
(11.0–12.9 g/dL for men, 11.0–11.9 g/dL for females), moderate
anemia (8.0–10.9 g/dL for males and females), severe anemia
(6.5–7.9 g/dL for males and females), and life-threatening
anemia (<6.5 g/dL for males and females). Patient case notes
and laboratory results were reviewed by 2 investigators (G.M.
and A.D.K.) and were used to classify patients into 5 mutually
exclusive groups based upon a primary clinical diagnosis:
newly diagnosed TB, clinical deterioration of known TB disease,
AIDS-deﬁning illness (other than TB), major organ dysfunction/
noncommunicable disease, or “other,” as previously described
[24]. “Cardiopulmonary illness” was deﬁned by any patient for
whom their primary admission diagnosis was related to a cardiac
and/or pulmonary disease, including newly diagnosed or wors-
ening TB disease. Creatinine levels upon admission were used
to calculate an estimated glomerular ﬁltration rate (eGFR) [27].
For multivariable analyses, a patient was considered to have
received a blood transfusion if they were transfused with RCC
at any point between 7 days before and 90 days after study entry.
All data analyses were conducted using Stata version 12.0
(College Station, TX). Proportions were compared using either
Fisher’s exact tests or χ2 tests, and medians were compared
using either Wilcoxon rank-sum tests or Kruskal–Wallis tests.
Multivariable logistic regression analyses were undertaken to
identify variables associated with receipt of a blood transfusion.
Cox proportional-hazards regression analyses were performed
to identify independent predictors of mortality in the ﬁrst 90
days after study enrollment and speciﬁcally to test whether
blood transfusions were independently associated with an in-
creased mortality risk. Person-time was accrued from the date
of hospital admission until death, LTFU, or censorship of
data at 90 days after hospital admission. Two multivariable
models were constructed that included receipt of blood transfu-
sions coded as a binary (yes/no), an ordinal (none, 1–3 [low],
4–7 [medium], ≥8 [high]), or a continuous variable (for each
unit increase). The ﬁrst model, “clinical model”, included
only prespeciﬁed factors most likely to inﬂuence a physician
to order a blood transfusion (blood hemoglobin level, a cardio-
pulmonary illness, and renal function). The second model,
“fully adjusted,” included prespeciﬁed factors (ie, blood hemo-
globin level, clinical diagnosis, conﬁrmed mycobacteremia,
renal function) and any covariates in the univariable models
meeting a predetermined cutoff of P < .1. Likelihood ratio
tests were used to investigate statistical hypotheses and interac-
tions between variables. All statistical tests were 2-sided at
α = 0.05.
RESULTS
Study Proﬁle
Of 609 patients with conﬁrmed HIV infection, 585 were en-
rolled, and, of these, 578 (98.8%) had admission hemoglobin
levels available and were included in this analysis. Patients
were typically young, and the majority were female (Table 1).
Approximately 85% of patients were aware of their positive
HIV-status on admission, but 36% had not yet commenced
ART, and viral load was suppressed in only 31% of all patients.
Advanced immunodeﬁciency was common (median CD4
count, 133 cells/µL), and approximately one half of patients
had previously been treated for TB disease (Table 1).
Anemia Diagnoses
The median hemoglobin level was 9.5 g/dL, and 84.8%
(n = 490) of all patients were anemic. Anemia was classiﬁed as
mild, moderate, severe, and life-threatening in 15.7% (n = 91),
38.4% (n = 222), 17.3% (n = 100), and 13.3% (n = 77) of 578 pa-
tients, respectively (Table 1). Greater anemia severity was asso-
ciated with younger age, a new HIV diagnosis, and having
started ART within the previous 90 days (Table 1). Those
with more severe anemia were also more likely to have more ad-
vanced immunodeﬁciency, higher HIV viral loads, higher CRP
levels, and lower eGFRs (Table 1). Lower mean corpuscular val-
ues and mean corpuscular hemoglobin values as well as in-
creased red cell distribution widths were also associated with
greater severity of anemia. In addition, those with greater ane-
mia severity were more likely to have symptoms suggestive of
TB and also have mycobacteremia (Table 1). Only 37 (6.4%)
of all patients were receiving a zidovudine (AZT)-containing
regimen, and AZT use was not associated with anemia severity.
Clinical Diagnoses Among Patients With Anemia
Patients were classiﬁed into 1 of 5 mutually exclusive groups
based on their primary diagnosis leading to hospital admission
(Table 2). Newly diagnosed TB disease was the most common
diagnosis among the overall cohort and accounted for almost
half of all diagnoses among those with severe or life-threatening
anemia. Approximately one quarter of patients with life-threatening
anemia had major organ dysfunction or a noncommunicable
disease. Acquired immune deﬁciency syndrome-deﬁning ill-
nesses other than TB did not constitute a large proportion of
those with more severe anemia.
Blood Transfusion Requirements and Associated Costs Among
All Patients
Within 90 days after hospital admission and study enrollment,
13.5% (n = 78) of all patients and 15.7% (n = 77) of patients
with anemia of any severity at the time of hospital admission
received at least 1 blood transfusion with RCC; 61.0% (n = 47)
of patients with life-threatening anemia at admission and 16.0%
(n = 16) of those with severe anemia at admission were
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Table 1. Baseline Characteristics by WHO/ACTG Anemia Severity Classiﬁcation (All Values Are Numbers [%] Unless Otherwise Stated)
Patient characteristics
All Patients,
n = 578 (100%)
No Anemia,
n = 88 (15.2%)
Mild Anemia,
n = 91 (15.7%)
Moderate Anemia,
n = 222 (38.4%)
Severe Anemia,
n = 100 (17.3%)
Life-threatening
Anemia, n = 77 (13.3%)
P
Value
Age, median (IQR) 35.4 (28.9–41.4) 37.4 (30.3–45.2) 38.0 (31.2–44.3) 34.8 (29.1–41.5) 32.9 (27.6–39.2) 32.8 (27.3–38.5) <.001
Female 333 (57.6) 49 (55.7) 42 (46.2) 137 (61.7) 61 (61.0) 44 (57.1) .134
HIV newly diagnosed 91 (15.7) 13 (14.8) 10 (11.0) 27 (12.2) 22 (22.0) 19 (24.7) .023
ART status
ART-naive 206 (35.6) 35 (39.8) 28 (30.8) 66 (29.7) 43 (43.0) 34 (44.2) .069
Current ART use 260 (45.0) 41 (46.6) 47 (51.7) 107 (48.2) 34 (34.0) 31 (40.3)
ART interrupted 112 (19.4) 12 (13.6) 16 (17.6) 49 (22.1) 23 (23.0) 12 (15.6)
Patients currently receiving ARTa
Treatment duration (years), median
(IQR)
1.0 (0.2–2.7) 1.8 (0.9–3.9) 0.7 (0.2–2.8) 0.7 (0.2–2.5) 0.9 (0.2–2.8) 0.7 (0.2–2.2) .081
ART for <90 d 67 (26.8) 4 (10.3) 10 (22.7) 32 (31.1) 13 (38.2) 8 (26.7) .048
AZT-containing regimen 37 (10.0) 7 (13.2) 6 (9.5) 18 (11.5) 3 (5.3) 3 (6.0) .574
Hematological tests, median (IQR)
Hemoglobin (g/dL) 9.5 (7.6–11.3) 13.6 (12.8–14.3) 11.5 (11.2–11.8) 9.5 (8.8–10.1) 7.5 (6.9–7.7) 5.4 (4.6–6.0) <.001
MCV (fL)b 89 (83–95) 94 (88–99) 91 (86–97) 89 (84–94) 84 (79–91) 85 (79–92) <.001
MCHC (g/dL)c 32.9 (32.1–33.7) 33.5 (32.9–34.2) 33.3 (32.6–34.0) 32.8 (32.1–33.6) 32.7 (31.6–33.3) 32.1 (30.9–32.8) <.001
RDW (%)c 14.5 (12.9–16.3) 13.1 (12.5–14.3) 13.4 (12.5–15.0) 14.6 (13.2–16.1) 15.3 (14.1–17.3) 16.3 (13.7–18.5) <.001
White cell count (×109 cells)d 6.9 (4.6–10.1) 6.4 (4.6–10.2) 7.3 (5.1–11.1) 7.0 (5.1–10.2) 6.5 (3.8–9.2) 7.0 (4.0–10.0) .109
Platelets (×109 cells)b 260 (188–355) 244 (178–309) 270 (206–397) 280 (195–356) 235 (175–338) 237 (140–383) .022
CD4 cell count (cells/μL), median
(IQR)e
133 (53–268) 239 (111–459) 200 (106–370) 129 (53–235) 72 (33–179) 71 (32–190) <.001
Log viral load (copies/mL), median
(IQR)f
4.2 (1.6–5.5) 3.6 (1.6–5.0) 3.7 (1.6–5.2) 4.0 (1.6–5.5) 5.4 (3.2–5.9) 4.2 (2.3–5.4) <.001
Viral suppression (viral load<400
copies/mL)
174 (31.0) 34 (39.1) 33 (37.1) 67 (30.6) 17 (18.3) 23 (31.1) .024
CRP (mg/L), median (IQR)g 71 (25–138) 21 (7–102) 59 (23–119) 73 (28–147) 100 (50–169) 90 (53–142) <.001
Creatinine (μmol/L), median (IQR)h 68 (52–93) 70 (54–84) 66 (53–83) 65 (51–84) 67 (52–109) 85 (52–194) .028
eGFR classification (mL/min/1.73 m2)h
<30 39 (6.8) 3 (3.5) 0 11 (5.0) 9 (9.0) 16 (20.8) <.001
≥30 538 (93.2) 84 (96.6) 91 (100) 211 (95.1) 91 (91.0) 61 (79.2)
Tuberculosis
Positive WHO symptom screene 537 (93.2) 74 (84.1) 83 (91.2) 208 (94.6) 98 (98.0) 74 (96.1) .003
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transfused. A total of 246 units were transfused, and the mean
number of units per patient was 3.2 (standard deviation = 2.3;
range, 1–12); 42.3% (n = 33) of those requiring at least 1 unit
of RCC had multiple blood transfusions within 90 days. The
cost of RCC alone (n = 246 units) in those requiring a blood
transfusion was 192 950 South African Rand (ZAR [$19 523
US dollars at study end date]). When service fees and taxes were
included, the total overall cost was 256 370 ZAR ($25 940), and
thus the mean cost per patient requiring transfusion was 3287
ZAR ($333).
Relationship Between Blood Transfusions and Mortality
Overall, 77 (13.3%) of patients died within 90 days, of which 68
(88.3%) had some degree of anemia; 16.9% (n = 13) had severe
and 24.7% (n = 19) had life-threatening anemia, respectively. Of
patients receiving a blood transfusion, 26.0% (n = 20) died com-
pared with 11.6% (n = 58) of patients who were not transfused
(P < .001). The 20 patients who died despite receiving a transfu-
sion typically had advanced immunodeﬁciency (median admis-
sion CD4 count, 68 cells/µL) and very severe anemia (median
hemoglobin level, 6.0 g/dL). In addition, a large proportion
had TB disease and additional signiﬁcant comorbidities (Sup-
plementary Table 1).
In univariable Cox regression analyses, receipt of blood trans-
fusion was associated with increased mortality risk, irrespective
of whether it was coded as a binomial, ordinal, or continuous
variable (Table 3). However, regardless of how receipt of
blood transfusions were coded, in multivariable analyses neither
model demonstrated evidence that blood transfusions were as-
sociated with a greater risk of mortality (Figure 1). Having an
eGFR < 30 (consistent with chronic renal disease) was indepen-
dently associated with mortality in all multivariable models.
Patients with a cardiopulmonary illness or those who were diag-
nosed with either an AIDS-deﬁning illness or noncommunicable
disease or major organ dysfunction also had an independently
higher mortality risk. Lower hemoglobin levels were indepen-
dently associated with poor survival in some but not all multivar-
iable models (Table 1 and Supplementary Table 2).
Factors Associated With Blood Transfusion in Patients With
Severe Anemia
The median hemoglobin at admission in patients receiving a
blood transfusion (n = 78) was 5.9 g/dL. The characteristics of
patients who received a transfusion were compared with those
of patients who did not; however, to improve clinical relevance,
analysis was restricted to those with severe or life-threatening
anemia (n = 177). Patients receiving a transfusion were more
likely (1) to have higher viral loads, (2) to have been previously
treated for TB, (3) to have mycobacteremia, and (4) to have an
admission diagnosis related to major organ dysfunction or a
noncommunicable disease (Supplementary Table 3). In multi-
variable models, only lower hemoglobin levels predicted receipt
of blood transfusion (Supplementary Table 4).Ta
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DISCUSSION
The large majority of HIV-infected adults requiring acute med-
ical admission to a South African district hospital were anemic,
and many had either severe or life-threatening anemia. A sub-
stantial proportion of such patients received at least 1 blood
transfusion, and, cumulatively, this cohort required the adminis-
tration of a large number of blood products. In contrast to earlier
reports from high-income settings, receipt of a blood transfusion
was not associated with an increased risk of short-termmortality
after adjusting for potential confounding variables.
Although patients requiring a blood transfusion were 2-fold
more likely to die in the ﬁrst 90 days, after adjusting for
confounding variables, receipt of blood transfusion was not
independently associated with increased mortality. This ﬁnding
is in contrast with 3 previous reports from the United States
showing that short-term mortality risk was increased among
HIV-infected patients requiring transfusion [11, 18, 19]. Several
theories have been proposed to explain this relationship, includ-
ing that blood transfusions may cause transient immunosup-
pression (transfusion immunomodulation), although this is
controversial [28]. Although one study found modestly in-
creased viral load among transfused HIV-infected patients,
the clinical signiﬁcance of the small increase in viral load was
not determined [20]. In previous studies, it was thought that
leukocytes in blood products may (1) directly activate HIV cel-
lular reservoirs, (2) lead to increased proviral transcription, (3)
cause immunosuppression, and (4) be associated with greater
mortality. However, this was largely disproved by a randomized
trial that demonstrated similar HIV-viral loads and survival
probabilities among HIV-infected patients receiving nonleuko-
cyte-reduced blood transfusions compared with those receiving
leukocyte-reduced blood transfusions [29]. It has also been
suggested that blood transfusions may increase mortality by
causing iron overload. Although iron excess is associated with
increased mortality in sub-Saharan Africa [30], this relationship
has not yet been conclusively proven. Finally, transfusion-
associated circulatory overload (TACO) may be associated with
mortality in HIV-infected patients with chronic severe anemia
(especially those with underlying cardiopulmonary disease),
but it is a relatively rare clinical phenomenon [12].
We and others suspect that the relationship between receipt
of blood transfusion and increased mortality risk reported in
previous studies more or less reﬂects an inherently higher mor-
tality risk among patients with advanced HIV who are likely to
be transfused compared with those who are not. In this way, re-
ceipt of a blood transfusion serves as a marker of overall disease
severity and mortality risk. Therefore, decreased survival may
simply represent confounding by indication [31]. In our
study, 20 patients died after receiving a transfusion, and such
patients were extremely ill, with advanced HIV disease, often
had disseminated TB disease, and most had several concomi-
tant copathologies. We carefully considered covariates possibly
confounding the relationship between blood transfusions and
mortality and adjusted for them accordingly. Even after doing
so, there was no evidence to suggest that an independent asso-
ciation existed between blood transfusion and greater mortality,
regardless of whether receipt of a transfusion was coded as a bi-
nomial, ordinal, or continuous variable. Previous studies in
which the relationship between transfusion and poor survival
persisted despite adjusting for potential confounders may also
have had residual confounding that is present to some degree
in all observational studies [31]. This possibility is partially sup-
ported by the ﬁnding that an independent relationship between
blood transfusions and higher mortality among AIDS patients
in New York did not persist after further adjusting for illness
Table 2. Overview of Primary Clinical Diagnosesa by WHO/ACTG Anemia Severity Classiﬁcation
Primary clinical diagnoses
All Patients
(n = 575)b
No Anemia
(n = 87)
Mild Anemia
(n = 91)
Moderate
Anemia (n = 221)
Severe Anemia
(n = 99)
Life-Threatening
Anemia (n = 77)
Newly diagnosed TB 196 (34.1) 22 (25.3) 23 (25.3) 71 (32.1) 52 (52.5) 28 (36.4)
Clinical deterioration of known TB 42 (7.3) 3 (3.5) 5 (5.5) 20 (9.1) 8 (8.1) 6 (7.8)
AIDS-defining illness other than TB 64 (11.1) 9 (10.3) 13 (14.3) 28 (12.7) 8 (8.1) 6 (7.8)
Major organ dysfunction or
noncommunicable disease
80 (13.9) 18 (20.7) 13 (14.3) 22 (10.0) 9 (9.1) 18 (23.4)
Other diagnosis 193 (33.6) 35 (40.2) 37 (40.7) 80 (36.2) 22 (22.2) 19 (24.7)
Abbreviations: AIDS, acquired immune deficiency syndrome; TB, tuberculosis; TB-IRIS, TB-associated immune reconstitution inflammatory syndrome; WHO,World
Health Organization.
a Patients were categorized into a primary clinical diagnosis according to the following methodology: (1) new TB diagnosis (took priority over other diagnoses); (2)
clinical deterioration of TB cases during treatment (included the following underlying causes: poor adherence, drug-resistant TB, TB-IRIS, hemoptysis, and
pneumothorax); (3) AIDS-defining illnesses other than TB (included: opportunistic infections and AIDS-related malignancies); (4) noncommunicable diseases
(included: non-AIDS cancer, diabetes, hypertensive complications, heart failure, and asthma) or major organ dysfunction not attributable to one of the above
categories (included: renal and liver failure, bone marrow dysfunction, seizures, and stroke). “Other diagnoses” included the following: other bacterial infection
(including pneumonia and dysentery) venous thromboembolism, drug-related (adverse effects or overdose), psychiatric illness, or other unclassifiable diagnoses.
b Three patients could not have a primary clinical diagnosis made based on available information.
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severity [18]. If present in our study, residual confounding is
probably accounted for by unrecorded markers of disease se-
verity, and if a further adjustment were possible, it would likely
be in favor of ﬁnding transfusions to not adversely affect prog-
nosis. Unmeasured confounders may possibly even mask a clin-
ical beneﬁt associated with receipt of blood transfusions.
In this patient population, which included patients who were
ART-naive and those receiving ART, 85% had anemia, and the
prevalence of severe or life-threatening anemia was more than
30%. Previous studies in sub-Saharan Africa have also reported
a similarly high prevalence of HIV-related anemia, sometimes
approaching as high as 90% [3, 5, 6, 32]; however, such estimates
are largely derived among ART-naive, ambulatory outpatients.
The high prevalence of severe or life-threatening anemia ob-
served in this study was in part due to the inclusion of patients
ill enough to seek acute medical attention, as well as advanced
Table 3. Cox Multivariable Analysis for Risk Factors Associated With Mortality (Blood Transfusion Coded as a Binary Variable)
Unadjusted HR
(95% CI)
P
Value
“Clinical Model” Adjusted
HR (95% CI)
P
Value
“Classic Model” Adjusted
HR (95% CI)
P
Value
Age, for each year increase 1.00 (.98–1.02) .961 1.00 (.98–1.03) .834
Male 1.02 (.65–1.60) .936 0.81 (.48–1.36) .415
ART status
Current use 1.0 .919
Naive 1.02 (.62–1.69)
Defaulted 1.13 (.62–2.05)
Previous history of TB treatment
No 1.0 .800
Yes 0.94 (.60–1.48)
History of shortness of breath
No 1.0 .733
Yes 1.08 (.69–1.69)
CD4 (cells/μL), for every 50-
unit decrease
1.10 (1.02–1.19) .004 1.06 (.97–1.15) .186
Viral load (copies/mL), for each
log-unit increase
0.99 (.87–1.13) .871
Hemoglobin (g/dL), for each
unit decrease
1.15 (1.06–1.25) .001 1.08 (.98–1.19) .096 1.09 (.98–1.22) .107
CRP (mg/L), for each 10-unit
increase
1.03 (1.01–1.06) .007 1.03 (1.00–1.06) .050
eGFR category (mL/min/1.73 m2)
eGFR ≥30 1.0 <.001 1.0 .001 1.0 .010
eGFR<30 3.72 (2.08–6.64) 3.04 (1.65–5.59) 2.54 (1.31–4.93)
Confirmed mycobacteremia
No 1.0 .102 1.0 .158
Yes 1.82 (.94–3.53) 1.97 (.78–4.93)
Clinical Diagnosis
“Other” 1.0 .002 1.0 <.001
New TB 1.10 (.59–2.05) 0.68 (.30–1.52)
Deterioration of TB 1.00 (.34–2.94) 1.03 (.33–3.21)
AIDS-defining illness (other
than TB)
3.40 (1.80–6.43) 3.40 (1.62–7.16)
NCD/MOD 1.84 (.92–3.67) 2.33 (1.05–5.14)
Cardiopulmonary illness
Yes 1.0 .050 1.0 .027
No 1.57 (1.00–2.49) 1.67 (1.05–2.64)
Received a blood transfusion
No 1.0 .002 1.0 .296a 1.0 .792a
Yes 2.34 (1.41–3.89) 1.40 (.75–2.63) 1.10 (.54–2.26)
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; HR, hazards ratio; MOD, major
organ dysfunction; NCD, noncommunicable disease; TB, tuberculosis.
a There was no evidence for interaction between receipt of blood transfusion and duration of follow-up (time).
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HIV/AIDS disease, and a high rate of opportunistic infections,
notably TB. Newly diagnosed TB was the primary diagnosis for
more than one third of all patients and accounted for nearly one
half of diagnoses among patients with severe or life-threatening
anemia. These results are entirely consistent with a study from
Malawi in which 43% of hospitalized HIV-infected patients
with severe anemia had TB [33] and provide further evidence
to suggest that anemia might have high predictive value for
HIV-associated TB in high-incidence settings [32, 34, 35]. In ad-
dition, patients in our study often had advanced HIV illness
with opportunistic infection or major organ dysfunction.
Thus, malignancies, nutritional deﬁciencies, and drug toxicities
may all have further contributed to the high observed preva-
lence and severity of anemia [36].
The large number of blood transfusions received by hospital-
ized, HIV-infected adults in the present study builds upon a
previous report from South Africa which demonstrated that
HIV-infected inpatients have higher transfusion requirements
than HIV-uninfected patients from the same hospital setting
and that such patients utilized a large number of blood products
[16]. In the present study, despite a large proportion of patients
being transfused, it is unclear whether patients had adequate
transfusion support because some patients with life-threatening
anemia were not transfused, and many of those who were trans-
fused received only 1–2 units of RCC. This may reﬂect several
factors, including patients presenting late to medical care in ex-
tremis and dying before transfusion and also that physicians
often prescribe blood transfusions based on a patient’s compos-
ite clinical picture and not hemoglobin level alone. There was
not a standardized institutional protocol for blood transfusions;
thus, some of these discrepancies are partially inﬂuenced by
variability in transfusion practice between doctors, depart-
ments, and hospitals. In addition, a perception by local physi-
cians of a shortage in supplies of blood products and their high
cost may have resulted in blood products being used sparingly
by some.
In many clinical settings in sub-Saharan Africa, there is a
shortage of “safe” blood products [37]. Although South Africa
has greater healthcare resources than most countries of sub-
Saharan Africa, inadequate quantities of blood is often still a
reality [38]. In this cohort, blood transfusions for 78 patients
accrued a cost of more than $25 000, which is likely an under-
estimate because this estimate did not include associated private
clinician’s fees and associated medical supplies, and thus trans-
fusions are associated with substantially increased overall
healthcare expenditure [39]. In view of these facts, improved
Figure 1. Adjusted hazard ratios and associated 95% conﬁdence intervals for mortality stratiﬁed by blood transfusion status. aModel #1 (clinical model)
adjusted for hemoglobin concentration, cardiopulmonary illness status, and renal function (estimated glomerular ﬁltration rate <30 mL/min/1.73 m2; yes or
no). bModel #2 (fully adjusted model) adjusted for age, gender, CD4 cell count, hemoglobin concentration, C-reactive protein concentration, renal function
(eGFR <30; yes or no), mycobacterial blood culture result, and primary clinical diagnosis category. The comparator group for all analyses was those who did
not receive a blood transfusion.
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solutions are needed to not only increase the availability of safe
and affordable blood products but also to reduce unnecessary
blood transfusions and to reduce requirements for blood prod-
ucts [37]. In this study, neither current ART use nor viral sup-
pression was associated with a decreased likelihood of blood
transfusion. However, patients requiring hospitalization despite
ART use and viral suppression are a minority and are not likely
representative of those receiving ART in the larger community.
Antiretroviral therapy is strongly associated with the resolution of
anemia in a majority of patients [3, 5, 6, 13, 14], and a previous
study found that ART was associated with decreased blood trans-
fusion requirements [40].Thus, increased ART coveragemay con-
tribute towards decreased patient morbidity, the increased
availability of blood products, and decreased healthcare costs. Pre-
scription of blood transfusions should be based on best practice
guidelines where available [12], and further studies are needed
to evaluate the impact of ART on blood product use (especially
large ART cohort studies), as well as additional strategies for re-
ducing blood transfusion requirements among both HIV-infected
and uninfected patients in sub-Saharan Africa [15, 41].
Strengths of this study include that this was a well character-
ized, prospectively recruited cohort that enrolled all HIV-infected
hospitalized adults requiring acute medical admission regard-
less of reason for admission. An additional strength was a
high ascertainment rate of vital status with <6% LTFU, despite
lack of routine follow-up in outpatient care. Nevertheless, mor-
tality was possibly underestimated because a proportion of pa-
tients LTFU may have died. We comprehensively searched for
transfusion requirements; however, the proportion of patients
transfused and their corresponding blood product use was likely
underestimated as patients occasionally report different names
or identifying information and may have presented to health-
care settings outside of the study hospital. This study was con-
ducted at a single site, and there was a relatively small number of
transfusions and patient deaths. It should also be noted that al-
though the lack of an independent association between blood
transfusions and mortality is likely to be generalizable to
other inpatient settings in sub-Saharan Africa, the proportion
of patients receiving blood transfusions and the associated use
of blood products represent point estimates and will undoubt-
edly vary across different settings for a number of reasons, in-
cluding variability in blood transfusion prescription practices.
Therefore, the transfusion requirements among patients in
this study should not be extrapolated to other settings.
CONCLUSIONS
More than 30% of HIV-infected hospitalized patients had severe
or life-threatening anemia, which resulted in a high proportion of
patients requiring a blood transfusion. Receipt of a blood trans-
fusion was not independently associated with greater mortality
risk. Thus, we found no evidence to support concerns regarding
the potential adverse impact of the administration of blood trans-
fusions to HIV-infected adults in sub-Saharan Africa.
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Supplementary material is available online at Open Forum Infectious
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